Author/Editor | Pongrac-Barlovič, Draženka; Thomas, Merlin C; Jandeleit-Dahm, Karin | |
Title | Cardiovascular disease: what's all the AGE/RAGE about? | |
Type | članek | |
Source | Cardiovasc Hematol Disord Drug Targets | |
Vol. and No. | Letnik 10, št. 1 | |
Publication year | 2010 | |
Volume | str. 7-15 | |
Language | eng | |
Abstract | Advanced glycation end-products (AGEs) are involved in mediating the effects of hyperglycaemia in diabetes. The most important receptor for AGEs is the receptor for advanced glycation end-products (RAGE). Binding of AGEs to RAGE converts transient cellular stimulation into sustained cellular dysfunction driven by long-term activation of the pro-inflammatory transcription factor NF-kB. Different splice variants of RAGE exist, including a soluble form that binds to AGEs but lacks the intracellular domain and thus fails to induce signal transduction. In this context, soluble RAGE may act as a therapeutic agent for AGE-induced effects. The balance between the synthesis of sRAGE and full-length RAGE may be an important determinant of AGE-induced dysfunction. An increasing amount of evidence suggests that AGEs either directly or via their interaction with RAGE play a pivotal role in the development and acceleration of atherosclerotic cardiovascular disease. These effects will be summarised in this review, together with the effects of therapeutic strategies targeting AGE/RAGE interactions. These treatments appear to have significant clinical potential, most likely in combination with currently used agents such as inhibitors of the renin-angiotensin system or statins, to reduce the major burden of diabetes, its associated cardiovascular disease. | |
Descriptors | CARDIOVASCULAR DISEASES GLYCOSYLATION END PRODUCTS, ADVANCED ATHEROSCLEROSIS DIABETES MELLITUS HYPERGLYCEMIA |